Table 2.
EFS and Patient Demographic and Clinical Characteristics in the Phase II Study
| Characteristic | No. of Patients | Events | EFS at 4 Months (%) | ||
|---|---|---|---|---|---|
| None | Relapse | Death | |||
| All eligible patients | 96 | 2 | 84 | 10 | 12 |
| Study and drug | |||||
| A09713 (topotecan) | 11 | 0 | 11 | 0 | * |
| ADVL0122 (imatinib) | 12 | 0 | 8 | 4 | * |
| ADVL0421 (oxaliplatin) | 13 | 2 | 9 | 2 | 0.31 |
| ADVL0524 (ixabepilone) | 11 | 0 | 10 | 1 | 0.09 |
| CCG0962 (docetaxel) | 22 | 0 | 21 | 1 | 0.23 |
| P9963 (rebeccamycin) | 17 | 0 | 16 | 1 | 0.06 |
| P9761 (irinotecan) | 10 | 0 | 9 | 1 | * |
| No. of prior treatment regimens | |||||
| 1 | 51 | 1 | 43 | 7 | 0.12 |
| 2 | 34 | 1 | 31 | 2 | 0.12 |
| ≥ 3 | 10 | 0 | 9 | 1 | 0.10 |
| Age, years | |||||
| < 9 | 11 | 0 | 10 | 1 | 0.09 |
| 10-17 | 40 | 0 | 39 | 1 | 0.08 |
| > 18 | 45 | 2 | 35 | 8 | 0.16 |
| Sex | |||||
| Male | 62 | 2 | 4 | 6 | 0.13 |
| Female | 34 | 0 | 30 | 4 | 0.09 |
| Race | |||||
| White | 58 | 1 | 49 | 8 | 0.10 |
| Black | 16 | 1 | 14 | 1 | 0.19 |
| Other | 22 | 0 | 21 | 1 | 0.09 |
Abbreviation: EFS, event-free survival.
*
No patients were observed for follow-up at 4 months.